Loading stock data…
$8.10+0.03 (+0.39%)
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
BioCryst Pharmaceuticals, Inc. in the Healthcare sector is trading at $8.10 with a market capitalization of $2.2B. Wall Street consensus targets $20.73 (11 analysts), implying a +155.9% move over the next 12 months. The stock is currently 28% below its 52-week high of $11.22, remaining 7.0% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $218.25M↑ | $156.41M↓ | $406.56M↑ | $159.40M↓ | $163.35M |
| Gross Profit | $214.41M↑ | $151.04M↓ | $397.03M↑ | $157.21M↓ | $160.56M |
| Operating Income | $98.47M↑ | -$701.60M↓ | $260.38M↑ | $29.59M↓ | $29.79M |
| Net Income | $78.39M↑ | -$721.81M↓ | $245.84M↑ | $12.90M↑ | $5.08M |
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatme...